Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aflibercept biosimilar - Alvotech

Next Previous
Drug Profile

Aflibercept biosimilar - Alvotech

Alternative Names: AVT-06; AVT-29

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alvotech
  • Developer Alvotech; Teva Pharmaceutical Industries
  • Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Retinal disorders; Wet age-related macular degeneration

Most Recent Events

  • 21 Mar 2025 Alvotech completes the phase III ALVOEYE-D trial in Retinal disorders in Georgia (Intravitreous) (NCT05986786)
  • 18 Feb 2025 Preregistration for Wet age-related macular degeneration in USA (Intravitreous) before February 2025
  • 18 Feb 2025 Alvotech anticipates regulatory approval for AVT 06 in the US in the fourth quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top